Home › Metabolic › Retatrutide (40mg)
Metabolic Research Peptide
Retatrutide (40mg)
GLP-1 / GIP / Glucagon triple-receptor agonist · Research-grade, Australia
In stock · dispatched Australia-wide
View & buy on store →About Retatrutide
Retatrutide (development code LY3437943) is a synthetic triple-agonist peptide that acts on three metabolic receptor targets at once: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This 30 mg presentation is the largest we offer, intended for extended laboratory study protocols.
The 40 mg presentation is the high-replicate format. Screening designs and plate-based work are limited less by concentration range than by how many wells one lot will fill, and at 40 mg the constraint usually moves off the compound entirely and onto plate capacity or reader throughput. It is also the lowest cost per milligram of the four retatrutide fills, which is the deciding factor when a protocol is already settled and the remaining work is repetition rather than exploration.
Receptor targets
- GLP-1 receptor — a target widely studied in incretin and glucose-regulation research.
- GIP receptor — an incretin receptor investigated alongside GLP-1 in metabolic-pathway studies.
- Glucagon receptor — a target studied in relation to energy expenditure and hepatic metabolism.
Molecular & physical profile
| Compound | Retatrutide |
|---|---|
| Synonym | LY3437943 |
| Category | Metabolic |
| CAS Number | 2381089-83-2 |
| Form | Lyophilised powder |
| Appearance | White to off-white solid |
| Quantity | 40 mg per vial |
| Purity | 99.850% (this batch) |
| Batch | CS-re30200 |
| Analytical methods | HPLC (purity), mass spectrometry (identity) |
| Solubility (research) | Reconstitutes in bacteriostatic or sterile water |
Batch-specific analytical values are recorded on the Certificate of Analysis supplied with this batch.
Reconstitution & handling
Retatrutide is supplied as a lyophilised powder and reconstitutes in bacteriostatic or sterile water. At 40 mg the reconstituted volume is substantial — 8 mL for a 5 mg/mL stock — and vial headroom becomes a practical consideration, so check the working volume before adding diluent. Reconstituting to a higher concentration in less volume and diluting from there is often the more manageable route at this fill weight.
Stock concentrations from a single 40 mg vial:
| 2 mL of diluent | 20 mg/mL stock |
|---|---|
| 4 mL of diluent | 10 mg/mL stock |
| 8 mL of diluent | 5 mg/mL stock |
| 10 mL of diluent | 4 mg/mL stock |
In-vitro stock concentrations for laboratory dilution work. Not dosing information.
Storage & stability
- Lyophilised powder — store at -20 °C, protected from light and moisture.
- Reconstituted solution — store at 2–8 °C and use within 28 days.
- Handling — minimise freeze–thaw cycles; keep vials sealed until use.
- Aliquoting — plan aliquot volumes before reconstituting. At 40 mg the number of single-use aliquots is large enough that container labelling and a written aliquot map matter as much as the freezing itself.
Why 40mg rather than a smaller fill
The four retatrutide presentations differ only in fill weight, and this one is chosen on replicate count and unit cost rather than on anything about the compound. Where the 30 mg vial answers a duration problem — one lot across a long calendar — the 40 mg vial answers a throughput problem: a settled protocol repeated across many wells or many replicates, at the lowest cost per milligram of the range.
It is the wrong choice for exploratory work. If the protocol is still being established, the 10 mg or 20 mg fills are the better starting point, because material committed to a design that then changes cannot be recovered and the 28-day post-reconstitution window does not pause while a protocol is revised.
Quality & testing
Every batch supplied by Vital Research Labs is analysed by an independent third-party laboratory. Purity is confirmed by high-performance liquid chromatography (HPLC) and identity by mass spectrometry (MS). The Certificate of Analysis for this batch is published in our CoA library once received.
Shipping within Australia
Retatrutide is dispatched from within Australia to Australian research customers, packaged discreetly and appropriately for a lyophilised research compound. Orders are processed on receipt of payment via bank transfer.
Frequently asked questions
Is Retatrutide available in Australia for research?
Yes. Vital Research Labs supplies research-grade Retatrutide (40mg) to Australian research customers, dispatched domestically. It is provided strictly for in-vitro laboratory research and is not for human or veterinary use.
What purity is your Retatrutide?
This batch is verified at 99.850% purity by third-party analytical testing (HPLC for purity, mass spectrometry for identity). The Certificate of Analysis for batch CS-re30200 is published in our CoA library.
How is Retatrutide tested?
Each batch is analysed by an independent third-party laboratory using HPLC to confirm purity and mass spectrometry to confirm identity. Batch-specific values are recorded on the Certificate of Analysis once testing is complete.
How should Retatrutide be stored?
The lyophilised powder is stored at -20 degrees C, protected from light and moisture. Once reconstituted for research it is kept at 2-8 degrees C and typically used within 28 days.
What is the difference between the 10mg, 20mg, 30mg and 40mg vials?
The compound is identical; only the quantity of lyophilised powder per vial differs. The 30mg presentation is intended for extended research protocols requiring more material, and offers a lower cost per milligram than the smaller presentations.
Is Retatrutide intended for human use?
No. Retatrutide (40mg) supplied by Vital Research Labs is intended strictly for in-vitro laboratory research and development. It is not a medicine or therapeutic good and is not for human consumption, veterinary use, or clinical application.
Where can I buy Retatrutide in Australia?
Vital Research Labs supplies Retatrutide from Australian stock, dispatched from New South Wales. Orders placed before the daily cut-off are dispatched the same business day, Monday to Friday, with tracked delivery Australia-wide including Sydney, Melbourne, Brisbane, Perth and Adelaide.
How long does delivery take?
Orders are dispatched the same business day payment is confirmed, Monday to Friday. Weekend and public holiday orders are dispatched the next business day. Standard and express options are available, and express shipping is free on orders over $200. Every order is sent tracked.
Is packaging discreet?
Yes. All orders are packed in plain, unbranded outer packaging with no indication of the contents, and sent tracked via Australia Post or an equivalent carrier.
What payment methods do you accept?
We accept Visa, Mastercard and American Express, plus Apple Pay and Google Pay, all taken instantly at checkout. Bank transfer is also available if you prefer.
What stock concentrations can a 40mg retatrutide vial be reconstituted to?
Reconstituting 40mg in 2mL of bacteriostatic water gives 20mg/mL; 4mL gives 10mg/mL; 8mL gives 5mg/mL; and 10mL gives 4mg/mL. Check vial working volume before adding larger volumes of diluent. These are in-vitro stock concentrations for laboratory dilution work only.
Who is the 40mg retatrutide vial for?
High-replicate and screening work on a protocol that is already settled. It is the lowest cost per milligram of the four retatrutide fills, so it suits repetition rather than exploration. For work where the protocol is still being established, a 10mg or 20mg fill wastes less if the design changes.
Is there a downside to the largest vial size?
Two. The reconstituted volume is large enough that vial headroom needs checking before diluent is added, and the 28-day post-reconstitution window applies to the whole fill regardless of size, so material has to be aliquoted and frozen promptly or it is lost. A larger fill is only economical if the study can actually use it.